{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:07:06Z","timestamp":1793416026681,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01AI105204-05"],"award-info":[{"award-number":["5R01AI105204-05"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["Intramural"],"award-info":[{"award-number":["Intramural"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here we present the development and characterization of an inactivated recombinant LASV and rabies vaccine candidate (LASSARAB) that expresses a codon-optimized LASV glycoprotein (coGPC) and is adjuvanted by a TLR-4 agonist (GLA-SE). LASSARAB elicits lasting humoral response against LASV and RABV in both mouse and guinea pig models, and it protects both guinea pigs and mice against LF. We also demonstrate a previously unexplored role for non-neutralizing LASV GPC-specific antibodies as a major mechanism of protection by LASSARAB against LF through antibody-dependent cellular functions. Overall, these findings demonstrate an effective inactivated LF vaccine and elucidate a novel humoral correlate of protection for LF.<\/jats:p>","DOI":"10.1038\/s41467-018-06741-w","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T14:44:09Z","timestamp":1538750649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-4734","authenticated-orcid":false,"given":"Tiago","family":"Abreu-Mota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie R.","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jahrling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gene","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wirblich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed F.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"6741_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","volume":"8","author":"S Paessler","year":"2013","unstructured":"Paessler, S. & Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. 8, 411\u2013440 (2013).","journal-title":"Annu. Rev. Pathol."},{"key":"6741_CR2","doi-asserted-by":"publisher","first-page":"e1002300","DOI":"10.1371\/journal.pmed.1002300","volume":"14","author":"CF Houlihan","year":"2017","unstructured":"Houlihan, C. F. et al. Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: a cross-sectional study. PLoS. Med. 14, e1002300 (2017).","journal-title":"PLoS. Med."},{"key":"6741_CR3","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1016\/S0140-6736(17)32092-5","volume":"390","author":"DM Pigott","year":"2017","unstructured":"Pigott, D. M. et al. Local, national, and regional viral haemorrhagic fever pandemic potential in Africa: a multistage analysis. Lancet 390, 2662\u20132672 (2017).","journal-title":"Lancet"},{"key":"6741_CR4","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1093\/infdis\/jiw239","volume":"214","author":"A Goba","year":"2016","unstructured":"Goba, A. et al. An outbreak of Ebola virus disease in the Lassa fever zone. J. Infect. Dis. 214, S110\u2013S121 (2016).","journal-title":"J. Infect. Dis."},{"key":"6741_CR5","unstructured":"Nigerian Centre for Disease Control. An update of Lassa fever outbreak in Nigeria, Vol. 19, May Report. (ed. Nigeria Centre for Disease Control) 1\u20136 (2018)."},{"key":"6741_CR6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","volume":"327","author":"JK Richmond","year":"2003","unstructured":"Richmond, J. K. & Baglole, D. J. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327, 1271\u20131275 (2003).","journal-title":"BMJ"},{"key":"6741_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B., Webb, P. A., Krebs, J. W., Johnson, K. M. & Smith, E. S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155, 437\u2013444 (1987).","journal-title":"J. Infect. Dis."},{"key":"6741_CR8","doi-asserted-by":"publisher","first-page":"e0006187","DOI":"10.1371\/journal.pntd.0006187","volume":"12","author":"EJ Mateer","year":"2018","unstructured":"Mateer, E. J., Huang, C., Shehu, N. Y. & Paessler, S. Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. PLoS. Negl. Trop. Dis. 12, e0006187 (2018).","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"6741_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","volume":"162","author":"KG Andersen","year":"2015","unstructured":"Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738\u2013750 (2015).","journal-title":"Cell"},{"key":"6741_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1743-422X-8-404","volume":"8","author":"LM Branco","year":"2011","unstructured":"Branco, L. M. et al. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol. J. 8, 404 (2011).","journal-title":"Virol. J."},{"key":"6741_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0049-5","volume":"3","author":"HJ Hallam","year":"2018","unstructured":"Hallam, H. J. et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccin. 3, 11 (2018).","journal-title":"NPJ Vaccin."},{"key":"6741_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/trstmh\/trv047","volume":"109","author":"AQ Mylne","year":"2015","unstructured":"Mylne, A. Q. et al. Mapping the zoonotic niche of Lassa fever in Africa. Trans. R. Soc. Trop. Med. Hyg. 109, 483\u2013492 (2015).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"6741_CR13","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","volume":"25","author":"R Carrion Jr.","year":"2007","unstructured":"Carrion, R. Jr. et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093\u20134102 (2007).","journal-title":"Vaccine"},{"key":"6741_CR14","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","volume":"74","author":"SP Fisher-Hoch","year":"2000","unstructured":"Fisher-Hoch, S. P., Hutwagner, L., Brown, B. & McCormick, J. B. Effective vaccine for lassa fever. J. Virol. 74, 6777\u20136783 (2000).","journal-title":"J. Virol."},{"key":"6741_CR15","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS. Med. 2, e183 (2005).","journal-title":"PLoS. Med."},{"key":"6741_CR16","doi-asserted-by":"publisher","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS. Negl. Trop. Dis. 9, e0003736 (2015).","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"6741_CR17","doi-asserted-by":"publisher","first-page":"e1005656","DOI":"10.1371\/journal.ppat.1005656","volume":"12","author":"L Oestereich","year":"2016","unstructured":"Oestereich, L. et al. Chimeric mice with competent hematopoietic immunity reproduce key features of severe Lassa fever. PLoS. Pathog. 12, e1005656 (2016).","journal-title":"PLoS. Pathog."},{"key":"6741_CR18","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/v4102031","volume":"4","author":"NE Yun","year":"2012","unstructured":"Yun, N. E. & Walker, D. H. Pathogenesis of Lassa fever. Viruses 4, 2031\u20132048 (2012).","journal-title":"Viruses"},{"key":"6741_CR19","doi-asserted-by":"publisher","first-page":"e1000836","DOI":"10.1371\/journal.ppat.1000836","volume":"6","author":"L Flatz","year":"2010","unstructured":"Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PLoS. Pathog. 6, e1000836 (2010).","journal-title":"PLoS. Pathog."},{"key":"6741_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jmv.1890120203","volume":"12","author":"PB Jahrling","year":"1983","unstructured":"Jahrling, P. B. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J. Med. Virol. 12, 93\u2013102 (1983).","journal-title":"J. Med. Virol."},{"key":"6741_CR21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/iai.44.2.528-533.1984","volume":"44","author":"PB Jahrling","year":"1984","unstructured":"Jahrling, P. B. & Peters, C. J. Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect. Immun. 44, 528\u2013533 (1984).","journal-title":"Infect. Immun."},{"key":"6741_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/v4010083","volume":"4","author":"JH Nunberg","year":"2012","unstructured":"Nunberg, J. H. & York, J. The curious case of arenavirus entry, and its inhibition. Viruses 4, 83\u2013101 (2012).","journal-title":"Viruses"},{"key":"6741_CR23","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin. Immunother. 13, 2902\u20132911 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"6741_CR24","first-page":"262","volume-title":"Vaccines (Basel)","author":"KA Cashman","year":"2013","unstructured":"Cashman, K. A. et al. Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines (Basel) 1, (262\u2013277 (2013)."},{"key":"6741_CR25","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"6741_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).","journal-title":"Nat. Commun."},{"key":"6741_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res. 133, 218\u2013222 (2016).","journal-title":"Antivir. Res."},{"key":"6741_CR28","doi-asserted-by":"publisher","first-page":"e1005276","DOI":"10.1371\/journal.ppat.1005276","volume":"11","author":"R Sommerstein","year":"2015","unstructured":"Sommerstein, R. et al. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS. Pathog. 11, e1005276 (2015).","journal-title":"PLoS. Pathog."},{"key":"6741_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.it.2015.04.005","volume":"36","author":"F Nimmerjahn","year":"2015","unstructured":"Nimmerjahn, F., Gordan, S. & Lux, A. FcgammaR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 36, 325\u2013336 (2015).","journal-title":"Trends Immunol."},{"key":"6741_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00928-3","volume":"8","author":"W He","year":"2017","unstructured":"He, W. et al. Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nat. Commun. 8, 846 (2017).","journal-title":"Nat. Commun."},{"key":"6741_CR31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"6741_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.immuni.2015.01.005","volume":"42","author":"DH Yamada","year":"2015","unstructured":"Yamada, D. H. et al. Suppression of Fcgamma-receptor-mediated antibody effector function during persistent viral infection. Immunity 42, 379\u2013390 (2015).","journal-title":"Immunity"},{"key":"6741_CR33","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/eji.201445386","volume":"45","author":"F Nimmerjahn","year":"2015","unstructured":"Nimmerjahn, F. A constant threat for HIV: Fc-engineering to enhance broadly neutralizing antibody activity for immunotherapy of the acquired immunodeficiency syndrome. Eur. J. Immunol. 45, 2183\u20132190 (2015).","journal-title":"Eur. J. Immunol."},{"key":"6741_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep45552","volume":"7","author":"Q Liu","year":"2017","unstructured":"Liu, Q. et al. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci. Rep. 7, 45552 (2017).","journal-title":"Sci. Rep."},{"key":"6741_CR35","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1016\/j.vaccine.2012.07.073","volume":"30","author":"AB Papaneri","year":"2012","unstructured":"Papaneri, A. B. et al. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine 30, 6136\u20136141 (2012).","journal-title":"Vaccine"},{"key":"6741_CR36","doi-asserted-by":"publisher","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","volume":"9","author":"JE Blaney","year":"2013","unstructured":"Blaney, J. E. et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS. Pathog. 9, e1003389 (2013).","journal-title":"PLoS. Pathog."},{"key":"6741_CR37","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","volume":"214","author":"RF Johnson","year":"2016","unstructured":"Johnson, R. F. et al. An inactivated Rabies virus-based Ebola vaccine, FILORAB1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models. J. Infect. Dis. 214, S342\u2013S354 (2016).","journal-title":"J. Infect. Dis."},{"key":"6741_CR38","doi-asserted-by":"publisher","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","volume":"212","author":"M Willet","year":"2015","unstructured":"Willet, M. et al. Preclinical development of inactivated Rabies virus-based polyvalent vaccine against Rabies and Filoviruses. J. Infect. Dis. 212, S414\u2013424 (2015). Suppl 2.","journal-title":"J. Infect. Dis."},{"key":"6741_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1743-422X-7-306","volume":"7","author":"LM Branco","year":"2010","unstructured":"Branco, L. M. et al. Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects. Virol. J. 7, 306 (2010).","journal-title":"Virol. J."},{"key":"6741_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1743-422X-6-147","volume":"6","author":"LM Branco","year":"2009","unstructured":"Branco, L. M. & Garry, R. F. Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol. J. 6, 147 (2009).","journal-title":"Virol. J."},{"key":"6741_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1743-422X-5-161","volume":"5","author":"MM Illick","year":"2008","unstructured":"Illick, M. M. et al. Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding. Virol. J. 5, 161 (2008).","journal-title":"Virol. J."},{"key":"6741_CR42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923\u2013928 (2017).","journal-title":"Science"},{"key":"6741_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.virol.2012.07.020","volume":"434","author":"AB Papaneri","year":"2012","unstructured":"Papaneri, A. B. et al. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 434, 18\u201326 (2012).","journal-title":"Virology"},{"key":"6741_CR44","doi-asserted-by":"publisher","first-page":"10605","DOI":"10.1128\/JVI.00558-11","volume":"85","author":"JE Blaney","year":"2011","unstructured":"Blaney, J. E. et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J. Virol. 85, 10605\u201310616 (2011).","journal-title":"J. Virol."},{"key":"6741_CR45","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","volume":"27","author":"SL Baldwin","year":"2009","unstructured":"Baldwin, S. L. et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27, 5956\u20135963 (2009).","journal-title":"Vaccine"},{"key":"6741_CR46","doi-asserted-by":"publisher","first-page":"e88979","DOI":"10.1371\/journal.pone.0088979","volume":"9","author":"CH Clegg","year":"2014","unstructured":"Clegg, C. H. et al. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PLoS ONE 9, e88979 (2014).","journal-title":"PLoS One"},{"key":"6741_CR47","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jviromet.2009.11.004","volume":"163","author":"N Ray","year":"2010","unstructured":"Ray, N., Whidby, J., Stewart, S., Hooper, J. W. & Bertolotti-Ciarlet, A. Study of Andes virus entry and neutralization using a pseudovirion system. J. Virol. Methods 163, 416\u2013423 (2010).","journal-title":"J. Virol. Methods"},{"key":"6741_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).","journal-title":"Sci. Rep."},{"key":"6741_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jim.2005.09.018","volume":"308","author":"VR Gomez-Roman","year":"2006","unstructured":"Gomez-Roman, V. R. et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308, 53\u201367 (2006).","journal-title":"J. Immunol. Methods"},{"key":"6741_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0092-8674(94)90115-5","volume":"76","author":"T Takai","year":"1994","unstructured":"Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J. V. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76, 519\u2013529 (1994).","journal-title":"Cell"},{"key":"6741_CR51","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1016\/j.vaccine.2017.07.101","volume":"35","author":"Q Li","year":"2017","unstructured":"Li, Q. et al. An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. Vaccine 35, 5172\u20135178 (2017).","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"6741_CR52","doi-asserted-by":"publisher","first-page":"S404","DOI":"10.1093\/infdis\/jiv188","volume":"212","author":"A Marzi","year":"2015","unstructured":"Marzi, A. et al. Stat1-deficient mice are not an appropriate model for efficacy testing of recombinant vesicular Stomatitis virus-Based Filovirus Vaccines. J. Infect. Dis. 212(Suppl 2), S404\u2013S409 (2015).","journal-title":"J. Infect. Dis."},{"key":"6741_CR53","doi-asserted-by":"publisher","first-page":"e1005263","DOI":"10.1371\/journal.ppat.1005263","volume":"11","author":"BA Rhein","year":"2015","unstructured":"Rhein, B. A. et al. Interferon-gamma Inhibits Ebola Virus Infection. PLoS Pathog. 11, e1005263 (2015).","journal-title":"PLoS Pathog."},{"key":"6741_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01669-z","volume":"8","author":"J Wen","year":"2017","unstructured":"Wen, J. et al. Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge. Nat. Commun. 8, 1459 (2017).","journal-title":"Nat. Commun."},{"key":"6741_CR55","unstructured":"World Health Organization. WHO Target Product Profile for Lassa virus Vaccine. (ed. World Health Organization) 1\u20139 (2017)."},{"key":"6741_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","volume":"16","author":"CR Fisher","year":"2018","unstructured":"Fisher, C. R., Streicker, D. G. & Schnell, M. J. The spread and evolution of rabies virus: conquering new frontiers. Nat. Rev. Microbiol. 16, 241\u2013255 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"6741_CR57","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","volume":"30","author":"MA Goicochea","year":"2012","unstructured":"Goicochea, M. A. et al. Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model. Vaccine 30, 1445\u20131452 (2012).","journal-title":"Vaccine"},{"key":"6741_CR58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1073\/pnas.86.1.317","volume":"86","author":"SP Fisher-Hoch","year":"1989","unstructured":"Fisher-Hoch, S. P. et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc. Natl Acad. Sci. USA 86, 317\u2013321 (1989).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6741_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0042-6822(89)90525-4","volume":"171","author":"HG Morrison","year":"1989","unstructured":"Morrison, H. G. et al. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology 171, 179\u2013188 (1989).","journal-title":"Virology"},{"key":"6741_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.virol.2005.01.019","volume":"335","author":"MP Rodriguez-Carreno","year":"2005","unstructured":"Rodriguez-Carreno, M. P. et al. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335, 87\u201398 (2005).","journal-title":"Virology"},{"key":"6741_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.virol.2017.09.013","volume":"512","author":"C Galan-Navarro","year":"2017","unstructured":"Galan-Navarro, C. et al. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. Virology 512, 161\u2013171 (2017).","journal-title":"Virology"},{"key":"6741_CR62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1128\/JVI.02308-14","volume":"89","author":"D Kurup","year":"2015","unstructured":"Kurup, D., Wirblich, C., Feldmann, H., Marzi, A. & Schnell, M. J. Rhabdovirus-based vaccine platforms against henipaviruses. J. Virol. 89, 144\u2013154 (2015).","journal-title":"J. Virol."},{"key":"6741_CR63","doi-asserted-by":"crossref","unstructured":"Wirblich C., et al. One-Health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and Rabies virus. J. Virol. 91, (2017).","DOI":"10.1128\/JVI.02040-16"},{"key":"6741_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","volume":"47","author":"S Bournazos","year":"2017","unstructured":"Bournazos, S. & Ravetch, J. V. Fcgamma Receptor Function and the Design of Vaccination Strategies. Immunity 47, 224\u2013233 (2017).","journal-title":"Immunity"},{"key":"6741_CR65","doi-asserted-by":"publisher","first-page":"19396","DOI":"10.1073\/pnas.1014515107","volume":"107","author":"F Nimmerjahn","year":"2010","unstructured":"Nimmerjahn, F. et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl Acad. Sci. USA 107, 19396\u201319401 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6741_CR66","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1073\/pnas.1203954109","volume":"109","author":"P Smith","year":"2012","unstructured":"Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl Acad. Sci. USA 109, 6181\u20136186 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6741_CR67","first-page":"513","volume":"3","author":"RN Harty","year":"2001","unstructured":"Harty, R. N., Brown, M. E., Hayes, F. P., Wright, N. T. & Schnell, M. J. Vaccinia virus-free recovery of vesicular stomatitis virus. J. Mol. Microbiol. Biotechnol. 3, 513\u2013517 (2001).","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"6741_CR68","doi-asserted-by":"publisher","first-page":"5897","DOI":"10.1016\/j.vaccine.2013.09.038","volume":"31","author":"AB Papaneri","year":"2013","unstructured":"Papaneri, A. B., Wirblich, C., Marissen, W. E. & Schnell, M. J. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: implication for post-exposure treatment. Vaccine 31, 5897\u20135902 (2013).","journal-title":"Vaccine"},{"key":"6741_CR69","doi-asserted-by":"publisher","first-page":"e13677","DOI":"10.1371\/journal.pone.0013677","volume":"5","author":"RN Coler","year":"2010","unstructured":"Coler, R. N. et al. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS ONE 5, e13677 (2010).","journal-title":"PLoS One"},{"key":"6741_CR70","doi-asserted-by":"publisher","first-page":"e0003793","DOI":"10.1371\/journal.pntd.0003793","volume":"9","author":"S Nikisins","year":"2015","unstructured":"Nikisins, S. et al. International external quality assessment study for molecular detection of Lassa virus. PLoS. Negl. Trop. Dis. 9, e0003793 (2015).","journal-title":"PLoS. Negl. Trop. Dis."},{"key":"6741_CR71","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458\u20131461 (2006).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06741-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T19:05:24Z","timestamp":1671563124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-06741-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["6741"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-06741-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.-M, P.B.J., and M.J.S. are inventors on the U.S. Provisional Patent Application No. 62\/691,413 (Title: Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever). All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4223"}}